研究者業績

清野 宏

キヨノ ヒロシ  (Hiroshi Kiyono)

基本情報

所属
千葉大学 未来医療教育研究機構 特任教授 (卓越教授)
学位
医学博士

J-GLOBAL ID
200901090720634306
researchmap会員ID
0000021773

外部リンク

Dr. Kiyono obtained his dental degree (D.D.S.) from Nihon University, and Ph. D. from the University of Alabama at Birmingham (UAB). His background as a dentist combined with extensive research experience in the field of Mucosal Immunology at UAB, Max-Planck Institute, Osaka University and now, the University of Tokyo make him exceptionally well qualified to lead the current and future directions of mucosal immunology and mucosal vaccine. To reflect his scientific contribution, he has been listed in ISI Highly Cited Researchers’ List since 2005. He is the past President of Society for Mucosal Immunology. He received of several prestigious awards including NIH New Investigator Research Award, NIH Research Career Development Award, The Japanese Society for Vaccinology Takahashi Award, and Hideyo Noguchi Memorial Medical Science Award. He has a total of 422 publications in peer review journals and edited a total of 20 books. He is currently Dean, the Institute of Medical Science, the University of Tokyo.

論文

 398
  • Yoshikazu Yuki, Shiho Kurokawa, Kotomi Sugiura, Koji Kashima, Shinichi Maruyama, Tomoyuki Yamanoue, Ayaka Honma, Mio Mejima, Natsumi Takeyama, Masaharu Kuroda, Hiroko Kozuka-Hata, Masaaki Oyama, Takehiro Masumura, Rika Nakahashi-Ouchida, Kohtaro Fujihashi, Takashi Hiraizumi, Eiji Goto, Hiroshi Kiyono
    Frontiers in Plant Science 15 2024年3月15日  
    We previously established the selection-marker-free rice-based oral cholera vaccine (MucoRice-CTB) line 51A for human use by Agrobacterium-mediated co-transformation and conducted a double-blind, randomized, placebo-controlled phase I trial in Japan and the United States. Although MucoRice-CTB 51A was acceptably safe and well tolerated by healthy Japanese and U.S. subjects and induced CTB-specific antibodies neutralizing cholera toxin secreted by Vibrio cholerae, we were limited to a 6-g cohort in the U.S. trial because of insufficient production of MucoRice-CTB. Since MucoRice-CTB 51A did not grow in sunlight, we re-examined the previously established marker-free lines and selected MucoRice-CTB line 19A. Southern blot analysis of line 19A showed a single copy of the CTB gene. We resequenced the whole genome and detected the transgene in an intergenic region in chromosome 1. After establishing a master seed bank of MucoRice-CTB line 19A, we established a hydroponic production facility with LED lighting to reduce electricity consumption and to increase production capacity for clinical trials. Shotgun MS/MS proteomics analysis of MucoRice-CTB 19A showed low levels of α-amylase/trypsin inhibitor-like proteins (major rice allergens), which was consistent with the data for line 51A. We also demonstrated that MucoRice-CTB 19A had high oral immunogenicity and induced protective immunity against cholera toxin challenge in mice. These results indicate that MucoRice-CTB 19A is a suitable oral cholera vaccine candidate for Phase I and II clinical trials in humans, including a V. cholerae challenge study.
  • Zhongwei Zhang, Izumi Tanaka, Rika Nakahashi-Ouchida, Peter B Ernst, Hiroshi Kiyono, Yosuke Kurashima
    Seminars in immunopathology 2024年1月3日  
    Glycoprotein 2 (GP2) is a widely distributed protein in the digestive tract, contributing to mucosal barrier maintenance, immune homeostasis, and antigen-specific immune response, while also being linked to inflammatory bowel disease (IBD) pathogenesis. This review sheds light on the extensive distribution of GP2 within the gastrointestinal tract and its intricate interplay with the immune system. Furthermore, the significance of GP2 autoantibodies in diagnosing and categorizing IBD is underscored, alongside the promising therapeutic avenues for modulating GP2 to regulate immunity and maintain mucosal balance.
  • Xiao Sun, Koji Hosomi, Atsushi Shimoyama, Ken Yoshii, Azusa Saika, Haruki Yamaura, Takahiro Nagatake, Hiroshi Kiyono, Koichi Fukase, Jun Kunisawa
    International Immunology 2023年11月25日  
    Abstract We previously demonstrated that Alcaligenes-derived lipid A (ALA), which is produced from an intestinal lymphoid tissue-resident commensal bacterium, is an effective adjuvant for inducing antigen-specific immune responses. To understand the immunologic characteristics of ALA as a vaccine adjuvant, we here compared the adjuvant activity of ALA with that of a licensed adjuvant (monophosphoryl lipid A, MPLA) in mice. Although the adjuvant activity of ALA was only slightly greater than that of MPLA for subcutaneous immunization, ALA induced significantly greater IgA antibody production than did MPLA during nasal immunization. Regarding the underlying mechanism, ALA increased and activated CD11b+ CD103− CD11c+ dendritic cells in the nasal tissue by stimulating chemokine responses. These findings revealed the superiority of ALA as a mucosal adjuvant due to the unique immunologic functions of ALA in nasal tissue.
  • Naomi Matsumoto, Shiho Kurokawa, Shigeyuki Tamiya, Yutaka Nakamura, Naomi Sakon, Shoko Okitsu, Hiroshi Ushijima, Yoshikazu Yuki, Hiroshi Kiyono, Shintaro Sato
    Viruses 15(9) 2023年9月15日  
    Sapoviruses, like noroviruses, are single-stranded positive-sense RNA viruses classified in the family Caliciviridae and are recognized as a causative pathogen of diarrhea in infants and the elderly. Like human norovirus, human sapovirus (HuSaV) has long been difficult to replicate in vitro. Recently, it has been reported that HuSaV can be replicated in vitro by using intestinal epithelial cells (IECs) derived from human tissues and cell lines derived from testicular and duodenal cancers. In this study, we report that multiple genotypes of HuSaV can sufficiently infect and replicate in human-induced pluripotent stem cell-derived IECs. We also show that this HuSaV replication system can be used to investigate the conditions for inactivation of HuSaV by heat and alcohol, and the effects of virus neutralization of antisera obtained by immunization with vaccine antigens, under conditions closer to the living environment. The results of this study confirm that HuSaV can also infect and replicate in human normal IECs regardless of their origin and are expected to contribute to future virological studies.
  • Yoshikazu Yuki, Norihiro Harada, Shin-Ichi Sawada, Yohei Uchida, Rika Nakahashi-Ouchida, Hiromi Mori, Tomoyuki Yamanoue, Tomonori Machita, Masakatsu Kanazawa, Dai Fukumoto, Hiroyuki Ohba, Takashi Miyazaki, Kazunari Akiyoshi, Kohtaro Fujihashi, Hiroshi Kiyono
    Vaccine 41(34) 4941-4949 2023年7月31日  
    Cationic cholesteryl-group-bearing pullulan nanogel (cCHP-nanogel) is an effective drug-delivery system for nasal vaccines. However, cCHP-nanogel-based nasal vaccines might access the central nervous system due to its close proximity via the olfactory bulb in the nasal cavity. Using real-time quantitative tracking of the nanogel-based nasal botulinum neurotoxin and pneumococcal vaccines, we previously confirmed the lack of deposition of vaccine antigen in the cerebrum or olfactory bulbs of mice and non-human primates (NHPs), rhesus macaques. Here, we used positron emission tomography to investigate the biodistribution of the drug-delivery system itself, cCHP-nanogel after mice and NHPs were nasally administered with 18F-labeled cCHP nanogel. The results generated by the PET analysis of rhesus macaques were consistent with the direct counting of radioactivity due to 18F or 111In in dissected mouse tissues. Thus, no depositions of cCHP-nanogel were noted in the cerebrum, olfactory bulbs, or eyes of both species after nasal administration of the radiolabeled cCHP-nanogel compound. Our findings confirm the safe biodistribution of the cCHP-nanogel-based nasal vaccine delivery system in mice and NHPs.

MISC

 642
  • 高橋 裕, 佐藤 慎太郎, 清野 宏, 山内 祥生, 佐藤 隆一郎
    日本生化学会大会プログラム・講演要旨集 96回 [2P-473] 2023年10月  
  • 佐藤 慎太郎, 植松 智, 清野 宏
    炎症と免疫 28(3) 248-252 2020年4月  
    腸管は我々の体内に存在するが、体表面を覆う皮膚と同様、つねに外的環境に曝されている。そこには個体にとって「非自己」である腸内細菌叢も存在し、免疫担当細胞や抗菌ペプチドなどを産生する上皮細胞と協働しながら絶妙なバランスを保ち、腸内の恒常性を維持していると考えられている。何らかの原因でこのバランスが崩れると、一時的に、時には慢性的に、炎症反応が誘発され、炎症性腸疾患などのような自己免疫疾患の原因になり得ることがわかってきた。(著者抄録)
  • So-Ichiro Hirata, Takahiro Nagatake, Kento Sawane, Koji Hosomi, Tetsuya Honda, Sachiko Ono, Noriko Shibuya, Emiko Saito, Jun Adachi, Yuichi Abe, Junko Isoyama, Hidehiko Suzuki, Ayu Matsunaga, Takeshi Tomonaga, Hiroshi Kiyono, Kenji Kabashima, Makoto Arita, Jun Kunisawa
    Allergy 2020年2月6日  
    BACKGROUND: Maternal dietary exposures are considered to influence the development of infant allergies through changes in the composition of breast milk. Cohort studies have shown that ω3 PUFA in breast milk may have a beneficial effect on the preventing of allergies in infants; however, the underlying mechanisms remain to be investigated. We investigated how the maternal intake of dietary ω3 PUFAs affects fatty acid profiles in the breast milk and their pups and reduced the incidence of allergic diseases in the pups. METHODS: Contact hypersensitivity (CHS) induced by 2,4-dinitrofluorobenzene and fluorescein isothiocyanate was applied to the skin in pups reared by mother maintained with diets mainly containing ω3 or ω6 PUFAs. Skin inflammation, immune cell populations and expression levels of immunomodulatory molecules in pups and/or human cell line were investigated by using flow cytometric, immunohistologic, and quantitative RT-PCR analyses. ω3 PUFA metabolites in breast milk and infant's serum were evaluated by lipidomics analysis using LC-MS/MS. RESULTS: We show that maternal intake of linseed oil, containing abundant ω 3 α-linolenic acid, resulted in the increased levels of ω 3 docosapentaenoic acid (DPA) and its 14-lipoxygenation products in the breast milk of mouse dams; these metabolites increased the expression of TNF-related apoptosis-inducing ligand (TRAIL) on plasmacytoid dendritic cells (pDCs) in their pups and thus inhibited infant CHS. Indeed, the administration of DPA-derived 14-lipoxygenation products to mouse pups ameliorated their DNFB CHS. CONCLUSION: These findings suggest that an inhibitory mechanism in infant skin allergy is induced through maternal metabolism of dietary ω3 PUFAs in mice.
  • Junya Isobe, Shintarou Maeda, Yuuki Obata, Keito Iizuka, Yutaka Nakamura, Yumiko Fujimura, Tatsuki Kimizuka, Kouya Hattori, Yun-Gi Kim, Tatsuya Morita, Ikuo Kimura, Stefan Offermanns, Takahiro Adachi, Atsuhito Nakao, Hiroshi Kiyono, Daisuke Takahashi, Koji Hase
    International immunology 2019年12月20日  
    Secretory immunoglobulin A, the most abundant antibody isotype in the body, maintains a mutual relationship with commensal bacteria and acts as a primary barrier at the mucosal surface. Colonization by commensal bacteria induces an IgA response, at least partly through a T-cell-independent process. However, the mechanism underlying the commensal-bacteria-induced T-cell-independent IgA response has yet to be fully clarified. Here, we show that commensal-bacteria-derived butyrate promotes T-cell-independent IgA class switching recombination (CSR) in the mouse colon. Notably, the butyrate concentration in human stools correlated positively with the amount of IgA. Butyrate upregulated the production of transforming growth factor β1 and all-trans retinoic acid by CD103+CD11b+ dendritic cells, both of which are critical for T-cell-independent IgA CSR. This effect was mediated by G-protein-coupled receptor 41 (GPR41/FFA3) and GPR109a/HCA2, and the inhibition of histone deacetylase. The butyrate-induced IgA response reinforced the colonic barrier function, preventing systemic bacterial dissemination under inflammatory conditions. These observations demonstrate that commensal-bacteria-derived butyrate contributes to the maintenance of the gut immune homeostasis by facilitating the T-cell-independent IgA response in the colon.
  • 柴田 納央子, 國澤 純, 安藤 正浩, 細川 正人, 堀井 俊平, 細見 晃司, 竹山 春子, 清野 宏
    日本生物工学会大会講演要旨集 2019年 213-213 2019年8月  

共同研究・競争的資金等の研究課題

 12